

Oncoinvent to Participate in Upcoming Virtual Investor Conferences

Oslo, Norway 15, February 2022

Oncoinvent AS, a clinical stage company advancing a pipeline of radiopharmaceutical products across a variety of solid cancers, today announced that members of management will participate in two upcoming virtual investor conferences:

- **B. Riley Radiation-Oncology Investor Day.** Fireside chat on Tuesday, February 22, 2022 at 10:30 a.m. ET.
- **2022 Credit Suisse London Healthcare Conference.** Company management will participate in 1x1 meetings on Wednesday, March 2, 2022.

About Oncoinvent

Oncoinvent AS is a clinical stage company developing innovative radiopharmaceutical technology that delivers precise, alpha-emitting particles across solid cancers. By leveraging internal manufacturing and supply chain capabilities to enable a clinical supply of radioisotopes, the company is advancing a pipeline of novel products that use alpha particles, a higher Linear Energy Transfer (LET) form of radiation, that can potentially eradicate cancer cells. Oncoinvent's lead candidate, Radspherin[®], is designed for treatment of metastatic cancers in body cavities, and its versatility allows it to be deployed for the treatment of a variety of cancer indications. Radspherin[®] is in two ongoing Phase 1 studies to treat peritoneal carcinomatosis from both ovarian cancer and colorectal cancer.

For further information, please contact:

Jan A. Alfheim, Chief Executive Officer

Cell: +47 46 44 00 45

Email: alfheim@oncoinvent.com

IR enquiries:

Courtney Turiano, Stern Investor Relations

Email: Courtney.Turiano@sternir.com